The April 1, 2026 release applies to services April 1 through September 30, 2026
Understanding AOD 9604: The Science Behind the Solution AOD 9604, short for "Advanced Obesity Drug," is a modified fragment of human growth hormone (HGH) specifically engineered to target fat metabolism.Unlike traditional HGH treatments, AOD 9604 focuses exclusively on fat burning without impacting blood sugar levels or cell growth
A phase I safety study in healthy adults confirmed that subcutaneous MOTS-c injections at doses up to 10 mg produced no serious adverse events, with a pharmacokinetic profile supporting once-daily or every-other-day dosing [3]
It may lead to symptoms such as tingling, numbness, and muscle problems
2018 Sep 24;18(11):81
However, always follow your doctor's instructions regarding the duration and dosage of any medicine